Hidradenitis suppurativa: clinic and diagnostics (part 2)

Abstract

The data on the clinical features and course of suppurative hidradenitis characterized by severe course and a tendency to relapse are presented. To select the treatment strategy the scale of the severity and staging process are proposed. The atypical localization of purulent suppurative hidradenitis and follicular occlusion tetrad, which also includes conglobata acne, folliculitis sycosiformis atrophicans / exfoliating scalp cellulitis and pilonidal abscess are described. It is proved that manifestation of suppurative hidradenitis are phenotypically heterogeneous. The role of genetic, comorbid factors, metabolic and hormonal disorders, as well as the role of the immune system in the development of the disease are discused. For the diagnosis index Sartorius (Sartorius score), microbiology, immunohistochemistry and other research methods, which largely determine the tactics of treatment of severe dermatosis were used.

Keywords

hidradenitis suppurativa / clinic / comorbid conditions / immunological disorders / diagnostics

References

[1] Esmann S., Dufour D.N., Jemec G.B. Questionnaire-based diagnosis of hidradenitis suppurativa: specificity, sensitivity and positive predictive value of specific diagnostic questions. Br. J. Dermatol. 2010; 163(1): 102-6.

[2] Lewis F., Messenger A.G., Wales J.K. Hidradenitis suppurativa as a presenting feature of premature adrenarche. Br. J. Dermatol. 1993; 129(4): 217-8.

[3] Scheinfeld N. Hidradenitis suppurativa in prepubescent and pubescent children. Clin. Dermatol. 2015; 33(3): 316-9.

[4] Von der Werth J.M., Jemec G.B. Morbidity in patients with hidradenitis suppurativa. Br. J. Dermatol. 2001; 144(4): 809-13.

[5] Gee B.C., Dawber R.P. Hidradenitis suppurativa. J. R. Soc. Med. 2000; 93(12): 661-2.

[6] Mortimer P.S., Lunniss P.J. Hidradenitis suppurativa. J. R. Soc. Med. 2000; 93(8): 420-2.

[7] Matusiak L., Bieniek A., Szepietowski J.C. Hidradenitis suppurativa and associated factors: still unsolved problems. J. Am. Acad. Dermatol. 2009; 61(1): 362-5.

[8] Демьянов С.Л., Корейба К.А., Жирнова Л.Р. Дифференциальная диагностика инфекций кожи и мягких тканей подмышечных областей. Практическая медицина. 2011; 49(1): 160-2.

[9] Михеев Г.Н., Аравийская Е.Р., Соколовский Е.В., Холодилова Н.А. Инверсные акне: современные представления о патогенезе, клинических проявлениях и терапии. Пластическая хирургия и косметология. 2010; 3: 433-8.

[10] Poli F., Wolkenstein P., Revuz J. Back and face involvement in hidradenitis suppurativa. Dermatology. 2010; 221(2): 137-41.

[11] Wortsman X., Jemec G.B. Real-time compound imaging ultrasound of hidradenitis suppurativa. Dermatol. Surg. 2007; 33(11): 1340-2.

[12] Jemec G.B., Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol. 1998; 39(6): 971-4.

[13] von Laffert M., Helmbold P., Wohlrab J., Fiedler E., Stadie V., Marsch W.C. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp. Dermatol. 2010; 19(6): 533-7.

[14] Canoui-Poitrine F., Revuz J.E., Wolkenstein P., Viallette C., Gabison G., Pouget F., et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J. Am. Acad. Dermatol. 2009; 61(1): 51-7. doi: 10.1016/j.jaad.2009.02.013.

[15] Culp C.E. Chronic hidradenitis suppurativa of the anal canal. A surgical skin disease. Dis. Colon Rectum. 1983; 26(10): 669-76.

[16] Jansen T., Plewig G. What’s new in acne inversa (alias hidradnitis suppurativa)? J. Eur. Acad. Dermatol. 2000; 14(5): 342-3.

[17] Plewig G., Jansen T. Acneiform dermatoses. Dermatology. 1998; 196(1): 102-7.

[18] Attanoos R.L., Appleton M.A., Douglas-Jones A.G. The pathogenisis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br. J. Dermatol. 1995; 33(1): 254-8.

[19] Yazdanyar S., Jemec G.B. Hidradenitis suppurativa: a review of cause and treatment. Curr. Opin. Infect. Dis. 2011; 24(2): 118-23.

[20] Jemec G.B., Faber M., Gutschik E., Wendelboe P. The bacteriology of hidradenitis suppurativa. Dermatology. 1996; 193(5): 203-6.

[21] Scheinfeld N. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol. Online J. 2013; 19(6): 18558.

[22] Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., Dietz W.H. The disease burden associated with overweight and obesity. JAMA. 1999; 282(16): 1523-9.

[23] Fimmel S., Zouboulis C.C. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010; 2(1): 9-16. doi: 10.4161/derm.2.1.12490.

[24] Fioravanti M., Lauraflori G., Guidelli G.M., Giordano N. Dactylitis as a first manifestation of arthritis associated with hidradenitis suppurativa. Indian J. Dermatol. Venereol. Leprol. 2011; 77(1): 74-6. doi: 10.4103/0378-6323.74999.

[25] Sabat R., Chanwangpong A., Schneider-Burrus S., Metternich D., Kokolakis G., Kurek A., et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012; 7(2): е31810. doi: 10.1371/journal.pone.0031810.

[26] Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288(21): 2709-16.

[27] Losanoff J.E., Sochaki P., Khoury N., Levi E., Salwen W.A., Basson M.D. Squamous cell carcinoma complicating chronic suppurative hydradenitis. Am. Surgeon. 2011; 77(11): 1449-53.

[28] Altunay I.K., Gokdemir G., Kurt A., Kaiaoglu S. Hidradenitis suppurativa and squamous cell carcinoma. Dermatol. Surg. 2002; 28(2): 88-90.

[29] Rowe D.E., Carroll R.J., Day C.L.Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. J. Am. Acad. Dermatol. 1992; 26(6): 976-90.

[30] Maclean G.M., Coleman D.J. Three fatal cases of squamous cell carcinoma arising in chronic perineal hidradenitis suppurativa. Am. R. Coll. Surg. Engl. 2007; 89(7): 709-12.

[31] Kołodziejczak M., Sudoł-Szopińska I., Wilczyńska A., Bierca J. Utility of transperineal and anal ultrasonography in the diagnostics of hidradenitis suppurativa and its differentiation from a rectal fistula. Postepy Hig. Med. Dosw. (Online). 2012; 66(2): 838-42. doi: 10.5604/17322693.1019537.

[32] Moosbrugger E.A., Mutasim D.F. Hidradenitis suppurativa complicated by severe lymphedema and lymphangiectasias. J. Am. Acad. Dermatol. 2011; 64(6): 1223-4.

[33] Onderdijk A.J., van der Zee H.H., Esmann S., Lophaven S., Dufour D.N., Jemec G.B.E. Depression in patients with hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2013; 27(2): 473-8.

[34] Ramasastry S.S., Conklin W.T., Granick M.S., Futrell J.W. Surgical management of massive perianal hidradenitis suppurativa. Ann. Plast. Surg. 1985; 15(3): 218-3.

[35] Joachim G., Acorn S. Stigma of visible and invisible chronic conditions. J. Adv. Nurs. 2000; 32(1): 243-8.

[36] Matusiak L., Bieniek A., Szepietowski J.C. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J. Am. Acad. Dermatol. 2010; 62(4): 706-8.

[37] Shavit E., Dreiher J., Freud T., Halevy S., Vinker S., Cohen A.D. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2015; 29(2): 371-6. doi: 10.1111/jdv.12567.

[38] Kurek A., Johanne Peters E.M., Sabat R., Sterry W., Schneider-Burrus S. Depression is a frequent co-morbidity in patients with acne inversa. J. Dtsch. Dermatol. Ges. 2013; 11(8): 743-50. doi: 10.1111/ddg.12067.

[39] Smith H.S., Chao J.D., Teitelbaum J. Painful hidradenitis suppurativa. Clin. J. Pain. 2010; 26(5): 435-44.

[40] Lavogiez C., Delaporte E., Darras-Vercambre S., Martin De Lassalle E., Castillo C., Mirabel X., et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010; 220(2): 147-53. doi: 10.1159/000269836.

[41] Van der Zee H.H., de Ruiter L., van den Broecke D.G., Dik W.A., Laman J.D., Prens E.P. Elevated levels of tumour necrosis factor (TNF)α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNFα and IL-1β. Br. J. Dermatol. 2011; 164(6): 1292-8. doi: 10.1111/j.1365-2133.2011.10254.x.

[42] Jemec G.B., Thomsen B.M., Hansen U. The homogeneity of hidradenitis suppurativa lesions. A histological study of intra-individual variation. APMIS. 1997; 105(5): 378-83.

[43] Mozeika E., Pilmane M., Nürnberg B.M., Jemec G.B. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. Acta Derm. Venereol. 2013; 93(3): 301-4. doi: 10.2340/00015555-1492.

[44] Leach R.D., Eykyn S.J., Phillips I., Corrin B., Taylor E.A. Anaerobic axillary abscess. Br. Med. J. 1979; 2(6181): 5-7.

RIGHTS & PERMISSIONS

Eco-Vector